Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

history * HIV-1 79

12th World AIDS Conference

- Keyword Abstract --
mong IDUs and natural of HIV infection in Ruili, China, 199 23244 ecombinant strains of
ed sex workers with no of injecting drug use, in New York c 23407 V3-loop amino acids of
/AIDS in prisons - The of life in prison as an indicator of ris 23555 ity and diversity among
e aetiology and natural of neutropenia in HIV disease/The 32152 n/Genetic evolution of
record important family and personal information for their c 33360 ntrapatient variability of
ited States/HIV testing among adults in the United States/ 43140 for the quantification of
eaving sex work: Work in a cohort of female sex workers in 43257 ization of South African
h application to natural studies/Estimation of date of HIV- 43472 ull-length sequences of
the medical and dental questionnaire of HIV+/AIDS patien 60248 nic epitopes shared by
mbai, India/The natural of HIV-1/2 in Mumbai, India/The n 60331 enetic recombination of
ngeneic lymphocytes in HIV-1-discordant identical twins/In vivo p 346*/42322 ces in Mexico between
or 5 (CCR5) gene in an HIV-1-infected patient/Homozygous 32 b 12105 ersubtype recombinant
antiretroviral therapy in patients/Positive influence 12116 d'lvoire/Distribution of
of disease among 2261 patients at a hospital in Ba 12144 scape recombinants of
s in long-term culture of cells/Drug combination stu 12362 3 sequence diversity of
of CD4+ T cell death in subjects: Inhibition by anti- 21160 encing of 4 East African
n by TNF-a produced by macrophages/Stimulation 21168 nfections in Cameroon/
nulomatous hepatitis in patients/Fever of unknown 22134 netic characterization of
ponse to IL-2 therapy in individuals heterozygous f 22419 geny-based analysis of
hocyte (CTL) activity in Ugandan adults/Cross-cla 31139 y in Cameroon/Study of
ne antibodies in sera of patients/Anti-chemokine a 31161 munological evaluation/
red by flow cytometry in subjects/CMV disease stat 31180 typing in distinguishing
d after anti-retroviral in subjects: A four-year follow 41193 n/Cloning of full-length
-cell count in a group of South African patients/Abil 42187 f the genetic diversity of
he peripheral nerve in individuals under stavudin 60023 /A unique recombinant
and monokine levels in patients with CD4+ T lymp 60132 he 1960s and 1970s/
ctivity of nitric oxide in cells/Apoptotic activity of n 60255 PCR-FLP/Subtyping of
o/HHV-6-independent HIV-1-infection of CD8+ T cells in vivo/HH 21130 scape recombinants of
system/Antigenicity of HIV-1-like Gag-V3 chimeric particles expre 21204 G-A hypermutation on
ion and enumeration of HIV-1-producing cells by ELISPOT (Enzy 42131 n of genetic subtypes of
n therapy/Worsening of HIV-1-related immune thrombocytopenia i 32154 Brazil/Seroreactivity to
kits for quantification of HIV-1-RNA in an open, prospective study i 60504 ariability in Morocco/
ous primers to quantify in clinical plasma samples/Ultr 60886 acterization of Russian
des in treatment-naive HIV-1-seropositive persons/Activity of sof 12145 e phenotype of primary
Bulk measurements of HIV-1-specific cytolytic T lymphocyte activ 31156 Vaginal transmission of
of genetically modified, syngeneic lymphocytes in 346*/42322 mpanzees/Dynamics of
agonists/Modulation of HIV-1 infection by CCR5 antagonists/Mod 56*/11103 BC) prevents spread of

f
tion of CCR5-mediated
s and cellular targets for
ant macrophage-tropic
-receptors used by NSI
o-receptor usage of an
use and MT2 tropism of
usage of tissue-derived
blocks T-cell line-tropic
lecular determinants of
ependent dual receptor
ad repeat sequence of
S therapy/Inhibition of
he E89G substitution in
activation of integrated
66 during the course of
eat shock modulation of
g and HIV-1 replication/
al RNA and protease of
nsmission of immature
ntification of a minimum
n viral infection/Role of
P) by expression of the
hemical localizations of
/Cell cycle G2 arrest by
s in mice transgenic for
lecular mechanisms of
5/CD95L pathway/The
a B patients after clonal
of infection/Diversity of
ines in the shedding of
ynamics during primary
mproved suppression of
operational?/Fitness of
II stages of infection/
ersistently infected with
infection/Interaction of
n different subtypes of
ecular epidemiology of
onoclonal antibodies to
Unique and highly novel
okine receptor usage of
y/Co-receptor usage of
/Analysis of full-length

infection by ccr5A32/Mechanism of 54*/11105 s in the pathogenesis of
in the human female genital tract/Co 10*/11106 ubjects co-infected with
selected by passage in cell culture/I 11110 m as determinant of the
strains that infect CD4+ T-cell lines, 11111 copper, and mortality in
isolate derived from HIV +ve person 11112 T-cell count/The role of
chimeric clones having envelope V3 11113 Uganda/Progression of
primary isolates obtained from patie 11116 e of death in a cohort of
entry/A small molecule CXCR4 inhib 11117 ncy/Control of maternal
tropism for human colonic cells and a 11118 a/Influence of maternal
infection vs. single receptor chemota 11120 n reduction of perinatal
gp41 dominantly interferes with wild- 11121 tality and neoplasms of
reverse transcription by actinomycin 376*/11124 eceptor gene in vertical
reverse transcriptase in regard to inc 11125 ty and mortality among
genomes in cell culture by CpG meth 11127 nization does not affect
infection/Potential protective effect 11128 urden in rapid pediatric
infection/Heat shock modulation of 11129 n one year after primary
Vif is an endogenous inhibitor of HIV- 377*/11130 mbasa, Kenya/Primary
on infectious virion assembly/The im 379*/11131 cute viral and chronic
during protease inhibitor treatment o 11132 inistered since primary
gag sequence required for particle a 11134 ir (141W94) therapy in
capsid phosphorylation in viral infecti 11135 s and CD4 increases in
gag gene in a Baculovirus system/Pr 11136 maintenance therapy in
Gag proteins and formation of O-sha 11138 DV) to reduce perinatal
Vpr is not responsible for Vpr-induce 11141 rogression of chronic
Vpr/T cell apoptosis in mice transge 11142 D for the treatment of
nuclear import: matrix antigen and V 381*/11144 minantly infected with
Nef protein induces CD4+ T-cell apo 11145 NVP) can reduce CSF
infection/Diversification of nef and v 11146 d children with perinatal
long terminal repeat sequences deri 11148 f nelfinavir in paediatric
in semen/Seminal cell-associated vi 279*/11151 ritonavir in children with
infection/Impact of a highly active an 11155 of HIV-1 protease/Antireplication over triple therapy/Altern 11156 (NVP): Suppression of
RT mutants: Is MOller's ratchet opera 11157 lity for the resistance of
cellular RNA load arise in late stage 11158 /Two-year durability of
/Characterization of a new long-term 11159 el series of dimerization
and hepatitis B virus (HBV) in mixed i 11160 C in antiretroviral-naive
can recombine and initiate a spreadi 11161 d functional changes in
genetic subtypes in West and Centra 430*/11163 V) plus 1 nucleoside in
/Immunologically-defined subgroups 11164 nd lamivudine (3TC) in
strains in HIV-1 + HIV-2 co-infected 11165 sine a novel inhibitor of
primary isolates of different genetic s 9*/11166 t nuclear localization of
isolates of different subtypes derived 211*/11167 cohort of symptomatic
RNA genomic sequences in the geni 11169 urveillance for group O

- Keyword Abstract
are frequently found among new full I 435*/11170
group O strains in Cameroun/Variab 11171
isolates from the Philippines/V3 Loo 11172
subtype A in African children present 11173
group O ANT70 during a ten year foil 11174
viral load in plasma: Influence of the 11175
isolates/Neutralization of South Afri 11176
subtypes A-J: Inter-subtype recombi 11177
virions of different genetic subtypes ( 11178
strains identified in China/Genetic re 429*/11179
subtype B, sexual preferences and r 11180
/The global spread of subtypes and i 11181
subtypes among HIV-1 positive tube 11182
in a dual-infected transfusion recipie 11183
subtype E in infected mothers and th 11184
reveals 2 recombinants and a geogr 11186
group M and HIV-1 group O co-infect 432*/11187
subtypes in Cameroon/Serologic an 11189
evolution in vivo/Phylogeny-based a 11190
env variability in Cameroon/Study of 11191
subtype D infection in Brazil: Molecul 11192
subtype B from non-B/Discordances 11193
genomes from recent infections in In 11194
group 0/Analysis of the genetic dive 11195,mixing subtypes A and H, found in a 11196
intrasubtype diversification originate 11197
in Mexico by envHMA and gagPCR- 11198
in a dually-infected transfusion recipi 11199
genome/Possible restrictions of G- 11200
from Korean patients with advanced 11201
peptides in pregnant women in Porto 11202
variability in Morocco/ 11203
subtype B isolate with unusual V3 lo 11204
isolates and their susceptibility to ne 11211
in Hu-PBL-SCID mice/Vaginal trans 11215
subtype B and E strains after simulta 11223
in brain tissue of SCID mice with HIV 556*/11233
infection/Role of CCR5A32 and CC 12110
and HTLV-2/CD4+ lymphocyte coun 12113
viral load/Haptoglobin polymorphis 12115
infected homosexual men/Plasma zi 12118
phenotype in viral pathogenesis and 12126
disease in rural Uganda/Progressio 12131
infected adults in Uganda/Outcome 12143
disease during pregnancy/Control o 459*/12151
and HIV-2 on child survival in Gambi 214*/12153
transmission/The potential role of int 12156
infected children: Long-term follow-u 12160
transmission and disease progressio 12162
infected and uninfected Kenyan chil 12163
progression in perinatally infected ch 12170
disease/Heart, lung, and immune ab 12171
infection with a zidovudine-resistant 12184
infection: Clinical manifestations am 333*/12186
infection: Persistently expanded me 12189
infection (PHI)/Long-term evaluatio 12199
infected antiretroviral naive subjects 286*/12204
infected patients with Rescriptor (DL 129*/12219
infection: Early results/ADAM study. 12229
transmission in PACTG 076/Lack of 12233
infected patients in very early stages 12238
infection in a Thai study population/ 12240
clade E/Study HIV-NAT 002: The sa 12241
viral load in pediatric patients with ad 12253
infection/Response to ritonavir in se 12254
infection/UK experience of nelfinavir 12258
/Combination antiretroviral therapy i 12259
activity of and HIV-1 resistance profil 12270
RNA to fewer than 50 copies/ml duri 12275
protease inhibitors/Importance of m 12277
load suppression in patients treated 12279
protease inhibitors/Peptidic "tongs" 12289
infected patients/Fortovase" (saqui 12301

infected patient during HAART/Lym 12302
infected patients/Potent and conven 12314
infected individuals/An open-label r 12357
replication/(-)-/-D-2,6-diaminopuri 12358
genome/Novel anti-retroviral compo 12370
infected adults in Nairobi, Kenya/Ev 12407
infections among African-born HIV in 13103